|Articles|March 1, 2004

Pharmacy Times

  • Volume 0
  • 0

Rebetol Oral Solution

Schering-Plough Corp (Kenilworth, NJ) has announced the launch of Rebetol (ribavirin USP) Oral Solution for use in combination with Intron A (interferon alfa- 2b, recombinant) Injection for treating pediatric chronic hepatitis C. The combination of Intron A and Rebetol is indicated for the treatment of patients 3 years of age and older with compensated liver disease previously untreated with alpha interferon. Rebetol Oral Solution represents a new formulation of ribavirin USP, developed specifically to meet the needs of pediatric patients. It comes in bubble-gum flavor. For more information, visit www.scheringplough. com.

Articles in this issue

almost 22 years ago

New Technologies Top Survey

almost 22 years ago

PDX Software Gets High Marks

almost 22 years ago

Seal•ON

almost 22 years ago

SaltAire Sinus Relief

almost 22 years ago

Zim's Crack Creme Hand Sanitizer

almost 22 years ago

CoroWise Plant Sterols

almost 22 years ago

Culturelle

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.


Latest CME